USD 2.03 billion
Asia Pacific Stem Cell Market Size, Share, Growth Analysis, By Product(Adult stem cells, induced pluripotent stem cells (iPSCs), embryonic stem cells, and others), By Technology(Cell acquisition, cell production, cryopreservation, and expansion and subculture), By Application(Clinical applications, and drug discovery and development), By Region - Industry Forecast 2024-2031
Report ID:
SQMIR35D2246 |
Region:
Regional |
Published Date: February, 2024
Pages:
157
|Tables:
91
|Figures:
76
Asia Pacific Stem Cell Market Insights
Asia Pacific Stem Cell Market size was valued at USD 2.21 billion in 2022 and is poised to grow from USD 2.41 billion in 2023 to 4.84 USD billion by 2031, at a CAGR of 9.1% during the forecast period (2024-2031)
The Asia-Pacific region is experiencing a rise in medical tourism, particularly in emerging countries like India and China. This growth can be attributed to various factors, including collaborations between Asian governments, international health agencies, and private firms, as well as significant investments in medical research and healthcare facilities. However, despite this positive outlook, the Asia-Pacific stem cell market may face certain challenges. These challenges include the absence of a structured finance arrangement, ethical concerns surrounding stem cell research, and difficulties associated with the preservation of stem cells.
The evaluation of the Asia-Pacific stem cell market encompasses several countries, namely China, Japan, India, Australia & New Zealand, South Korea, Thailand, Indonesia, Vietnam, and the rest of the Asia Pacific region. China, in particular, has witnessed substantial growth in its stem cell market due to increased government involvement in strengthening the nation's biotech industry. The Chinese government allocated $18 billion to biotechnology research in its latest five-year plan, which has significantly contributed to the growth of the stem cell market. Moreover, China benefits from a supportive regulatory framework for stem cell research, along with growing private and public initiatives to promote the use of stem cell treatments. The expansion and modernization of healthcare infrastructure in China further fuel the growth of the stem cell market in the country.
Meanwhile, Japan has made significant contributions to stem cell therapies over the years, primarily driven by the importance of stem cells in treating incurable diseases. Japan is expected to be one of the most lucrative regions in the stem cell market, with a particular focus on induced pluripotent stem cells, which hold great potential in the field of regenerative medicine. In 2022, Japan-Metcela acquired Japan Regenerative Medicine Co Ltd, a subsidiary of Kidswell Bio Co Ltd, to enhance its pipeline with an autologous cell product for pediatric congenital heart disease. This acquisition will strengthen the clinical development infrastructure for regenerative medicine products in Japan. Consequently, these factors are anticipated to drive the growth of the stem cell market in the Asia-Pacific region during the forecast period.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
Adult Stem Cells (ASCs)
Fastest Growth
Adult Stem Cells (ASCs)
Growth Rate
9.1% CAGR
Asia Pacific Stem Cell Market ($ Bn)
States Share for China Country (%)
To get more reports on the above market click here to Buy The Report
Asia Pacific Stem Cell Market Segmental Analysis
Asia Pacific Stem Cell Market is segmented on the basis of product, technology, application, therapeutic application, treatment type, and country. By product, the market is segmented into adult stem cells, induced pluripotent stem cells (iPSCs), embryonic stem cells, and others. By technology, the market is segmented into cell acquisition, cell production, cryopreservation, and expansion and subculture. By application, the market is segmented into clinical applications, and drug discovery and development. By therapeutic application, the market is segmented into neurology, orthopedic, oncology, cardiovascular, dermatology, and others. By treatment type, the market is segmented into allogeneic stem cell therapy and autologous stem cell therapy. By country, the market is segmented into China, Japan, India, Australia & New Zealand, South Korea, Thailand, Indonesia, Vietnam, and the Rest of Asia Pacific.
Asia Pacific Stem Cell Market Analysis By Product
In the Asia-Pacific stem cell market, the largest segment in terms of product is adult stem cells. Adult stem cells have gained significant prominence in regenerative medicine due to their potential for differentiation into various cell types and their ability to repair and regenerate damaged tissues. These cells can be sourced from different tissues and organs such as bone marrow, adipose tissue, and umbilical cord blood. Adult stem cells hold a dominant position in the market due to their established safety profile, extensive research, and clinical applications. They have been successfully used in treating a range of conditions, including cardiovascular diseases, orthopedic disorders, and neurological disorders. The versatility and accessibility of adult stem cells contribute to their popularity, as they can be easily harvested from the patient's own body, reducing the risk of immune rejection.
On the other hand, the fastest-growing segment in the Asia-Pacific stem cell market is induced pluripotent stem cells (iPSCs). iPSCs are reprogrammed adult cells that possess the remarkable ability to differentiate into any cell type in the body. This feature makes iPSCs highly attractive for regenerative medicine applications, as they offer the potential to replace damaged or diseased tissues and organs. The rapid growth of iPSCs can be attributed to several factors. Firstly, iPSCs eliminate the ethical concerns associated with embryonic stem cells, making them a more widely accepted option. Additionally, iPSCs can be generated from a patient's own cells, providing a personalized approach to treatment and minimizing the risk of immune rejection. Furthermore, ongoing research and advancements in iPSC technology have expanded their applications and improved their efficiency, fueling their market growth.
Asia Pacific Stem Cell Market Analysis By Therapeutic Application
Among the various therapeutic applications, neurology emerges as the largest segment, while oncology stands out as the fastest-growing segment in the region. Neurology, encompassing the treatment of neurological disorders and injuries, holds a dominant position within the Asia-Pacific stem cell market. With an increasing prevalence of conditions like Parkinson's disease, Alzheimer's disease, and spinal cord injuries in the region, the demand for effective and innovative treatment options has surged. Stem cell therapies offer immense potential in regenerating damaged neural tissues and restoring neurological functions, providing hope for patients and caregivers alike. The neurology segment's significance can be observed through its substantial market share, accounting for a significant portion of the overall Asia-Pacific stem cell market. This underscores the growing recognition of stem cell-based treatments as a viable therapeutic approach for addressing neurodegenerative and neurodevelopmental disorders.
On the other hand, the oncology segment is experiencing remarkable growth and is projected to be the fastest-growing segment within the Asia-Pacific stem cell market. Stem cell therapies hold tremendous promise in the field of oncology, contributing to advancements in cancer treatment and management. These therapies have shown potential in regenerating healthy blood and immune cells destroyed during aggressive cancer treatments like chemotherapy and radiation therapy. Additionally, stem cells can be used to develop targeted therapies and personalized treatment approaches, improving patient outcomes. The rapid growth of the oncology segment is fueled by several factors. Firstly, the rising incidence of cancer cases in the Asia-Pacific region, coupled with the increasing demand for effective and less invasive treatment options, has created a favorable market environment. Secondly, the advancements in stem cell research and the development of novel therapeutic applications have propelled the adoption of stem cell-based therapies in oncology. Lastly, the supportive regulatory landscape and government initiatives promoting cancer research and treatment in countries like China and Japan have further facilitated market growth.
Asia Pacific Stem Cell Market By Product
To get detailed analysis on other segments, Request For Free Sample Report
Asia Pacific Stem Cell Market Regional Insights
China dominated the Asia Pacific stem cell market, while India stands out as the fastest-growing region, showcasing remarkable potential and attracting significant attention from investors and healthcare stakeholders.
China, with its robust infrastructure, supportive regulatory framework, and substantial investments in biotechnology research, holds a commanding position in the Asia-Pacific stem cell market. The Chinese government has allocated a staggering $18 billion to biotechnology research in its latest five-year plan, highlighting the nation's commitment to fostering innovation and development in the field. This has propelled China to the forefront of stem cell research and treatments, driving market growth in the region. With its vast population and increasing medical tourism, China's stem cell market commands a significant market share, contributing significantly to the overall Asia-Pacific market dynamics.
India, on the other hand, emerges as the fastest-growing region in the Asia-Pacific stem cell market, experiencing a surge in demand for stem cell therapies and regenerative medicine. The country's rising prominence can be attributed to factors such as a large patient pool, increasing awareness about the benefits of stem cell treatments, and a supportive regulatory environment. India's stem cell market has witnessed significant investments in research and healthcare infrastructure, further propelling its growth. With a robust ecosystem for stem cell research and clinical applications, India has attracted global attention and collaborations, leading to accelerated market expansion. The stem cell market in India is projected to witness substantial growth, capturing a notable market share in the Asia-Pacific region.
Asia Pacific Stem Cell Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Asia Pacific Stem Cell Market Dynamics
Asia Pacific Stem Cell Market Drivers
Supportive Government Initiatives
- Governments in the Asia-Pacific region have been actively supporting and promoting stem cell research and therapies. They have established favorable regulatory frameworks, allocated funding for research and development, and facilitated collaborations between academic institutions, hospitals, and industry players. For instance, in Japan, the government has implemented the Regenerative Medicine Promotion Act, providing a pathway for accelerated approval of regenerative medicine products, including stem cell therapies. Such initiatives encourage innovation, attract investments, and drive the growth of the stem cell market.
Asia Pacific Stem Cell Market Restraints
Ethical Concerns
- The Asia-Pacific stem cell market faces ethical challenges associated with the use of embryonic stem cells. The extraction of embryonic stem cells from early-stage embryos raises ethical dilemmas and has resulted in regulatory restrictions in some countries. These concerns limit the availability and utilization of embryonic stem cells for research and therapeutic purposes.
Request Free Customization of this report to help us to meet your business objectives.
Asia Pacific Stem Cell Market Competitive Landscape
The Asia-Pacific stem cell market is characterized by the presence of a diverse range of players, including both regional and international companies. Several prominent companies have established their dominance in the market, leveraging their expertise in stem cell research, clinical applications, and technological advancements. These key players focus on strategic collaborations, partnerships, and mergers and acquisitions to expand their product portfolios, strengthen their market presence, and gain a competitive edge. Additionally, they invest significantly in research and development activities to drive innovation and develop novel stem cell therapies. Some of the leading companies operating in the Asia-Pacific stem cell market constantly strive to enhance their product offerings, expand their geographical reach, and maintain a strong foothold in the dynamic and evolving stem cell market of the Asia-Pacific region.
Asia Pacific Stem Cell Market Top Player’s Company Profile
- Fujifilm Holdings Corporation (Japan)
- Mesoblast Limited (Australia)
- Hitachi, Ltd. (Japan)
- Lonza Group Ltd. (Switzerland)
- Celgene Corporation (US)
- STEMCELL Technologies Inc. (Canada)
- Takara Bio Inc. (Japan)
- Medipost Co., Ltd. (South Korea)
- Cell Biotech Co., Ltd. (South Korea)
- Roche Holding AG (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- Daiichi Sankyo Company, Limited (Japan)
- Sysmex Corporation (Japan)
- Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Wuxi AppTec Co., Ltd. (China)
- Japan Tissue Engineering Co., Ltd. (Japan)
- Kaken Pharmaceutical Co., Ltd. (Japan)
- Regeneus Ltd. (Australia)
Asia Pacific Stem Cell Market Recent Developments
- In May 2021, MEDIPOST announced the expansion of its production facilities for knee osteoarthritis stem cell products, namely CARTISTEM and SMUP-IA-01. The company revealed its plans to commence preparations for obtaining GMP (Good Manufacturing Practice) certification. This expansion signifies MEDIPOST's commitment to meeting the increasing demand for effective stem cell treatments for knee osteoarthritis. By expanding their production facilities and striving for GMP certification, MEDIPOST aims to ensure the highest quality standards in the manufacturing process of their stem cell products, reinforcing their position in the market and enhancing patient confidence in their therapies.
- In February 2022, Mesoblast held discussions with the FDA, following a meeting held in December 2021, to discuss the approval request for its therapy. During the meeting, Mesoblast presented "substantial new data" that demonstrated the therapy's clinical effect through its immunomodulatory activity. This evidence indicates that measuring the therapy's impact on the immune system is an appropriate indicator of its clinical efficacy. By engaging with the FDA and providing compelling data, Mesoblast aims to strengthen its case for approval and advance the potential availability of its therapy to patients in need.
Asia Pacific Stem Cell Key Market Trends
- Emergence of Off-the-Shelf Stem Cell Products: Another trend in the Asia-Pacific stem cell market is the emergence of off-the-shelf stem cell products. Efforts are being made to develop standardized, quality-controlled stem cell products that can be readily available for clinical use without the need for individualized cell production. This trend aims to overcome challenges associated with scalability, cost, and logistics in personalized cell therapies. For example, South Korean companies are actively working on developing allogeneic stem cell products for various therapeutic applications, including orthopedics and dermatology. The availability of off-the-shelf stem cell products has the potential to streamline treatment procedures, expand accessibility, and drive market growth.
Asia Pacific Stem Cell Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Product types team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our Asia Pacific Stem Cell market analyses, the market is poised for significant growth in the coming years. Factors driving this growth include the rising trend of medical tourism in emerging countries like India and China, government initiatives to strengthen the biotech industry, and substantial investments in medical research and healthcare infrastructure. The region's largest segment, neurology, offers immense potential for stem cell therapies in addressing neurological disorders and injuries. Additionally, the oncology segment is expected to be the fastest-growing, driven by increasing cancer incidence and the demand for innovative and personalized treatment options. With supportive regulatory frameworks, advancements in technology, and a growing patient population, the Asia-Pacific stem cell market presents attractive opportunities for stakeholders in the field of regenerative medicine.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 2.21 billion |
| Market size value in 2031 | USD billion |
| Growth Rate | 9.1% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Asia Pacific Stem Cell Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Asia Pacific Stem Cell Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Asia Pacific Stem Cell Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Asia Pacific Stem Cell Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Asia Pacific Stem Cell Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Asia Pacific Stem Cell Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
